Mitochondrial mutation status, symptom prevalence, and neuroimaging characteristics in MELAS: a systematic review and meta analysis
Abstract
Background: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is a rare mitochondrial disorder characterized by a wide range of systemic manifestations. MELAS is challenging to diagnose in its early stages and currently lacks targeted treatments. This systematic review and meta-analysis aim to validate the mitochondrial 3243A > G (m.3243A > G) mutation status, symptom prevalence, and neuroimaging characteristics in patients with MELAS. The review also seeks to consolidate and clarify the pathogenic pathways of MELAS while pinpointing potential therapeutic targets.
Main body: We searched four databases for relevant studies. Study selection, data extraction, and quality assessment using the JBI (Joanna Briggs Institute) scale were performed by two reviewers. We conducted meta-analyses to estimate the pooled proportions for genetic, symptomatic, and imaging features using the random-effects generalized linear mixed model. In addition, seven MELAS-related pathways were researched, and their gene information was expanded through computational retrieval from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome databases. A total of 13 studies involving 988 subjects were included, covering one mutant gene (m.3243A > G), ten clinical symptoms, and four imaging features. The meta-analyses showed a pooled m.3243A > G mutation prevalence of 78% (95% CI: 68%, 86%). The most frequent clinical manifestations were stroke-like episodes (99%; 95%…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 988 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.